A number of factors should be considered at this stage:

• the patient’s overall condition, life expectancy, personal preferences and decision-making capacity
• discussing the multidisciplinary team approach to care with the patient
• appropriate and timely referral to an MDM
• pregnancy and fertility
• support with travel and accommodation
• teleconferencing or videoconferencing as required
• additional tests to calculate the relevant prognostic scores for each low-grade lymphoma
• evaluation of relevant organ function based on history, clinical examination and, where appropriate, laboratory or imaging investigations (cardiac, respiratory, renal, hepatic)
• autoimmune screens (these are sometimes warranted in MZL, specifically autoimmune haemolytic anaemia)
• tests for occult infections (e.g. HIV, hepatitis B and C, tuberculosis) that may be affected by therapy or pose a risk of reactivation due to the immunosuppressive effects of For MZL, site-specific infectious disease testing should be performed.